	US 12,303,724 B2
	Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer
Adedigbo Fasanmade, Cambridge, MA (US)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed on Sep. 2, 2022, as Appl. No. 17/902,240.
Application 17/902,240 is a continuation of application No. 16/349,499, granted, now 11,464,869, previously published as PCT/US2017/061294, filed on Nov. 13, 2017.
Claims priority of provisional application 62/421,527, filed on Nov. 14, 2016.
Prior Publication US 2023/0136346 A1, May 4, 2023
Int. Cl. A61P 35/00 (2006.01); A61K 31/475 (2006.01); A61K 31/573 (2006.01); A61K 31/655 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); A61P 35/02 (2006.01); C07K 16/28 (2006.01)

CPC A61K 47/6889 (2017.08) [A61K 31/475 (2013.01); A61K 31/573 (2013.01); A61K 31/655 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/68031 (2023.08); A61K 47/6811 (2017.08); A61K 47/6817 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); C07K 2317/24 (2013.01); C07K 2317/90 (2013.01); C07K 2317/94 (2013.01)]

14 Claims

1. A method of treating a hematological or lymphoid cancer in a non-adult human subject comprising administering to the subject brentuximab vedotin at a body surface area adjusted dose of 71.5 mg/m², wherein the hematological or lymphoid cancer expresses CD30.